Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16719
Title: The Post-SIR-Spheres Surgery Study (P4S): retrospective analysis of safety following hepatic resection or transplantation in patients previously treated with selective internal radiation therapy with yttrium-90 resin microspheres
Authors: Pardo, Fernando
Sangro, Bruno
Lee, Rheun-Chuan
Manas, Derek
Jeyarajah, Rohan
Donckier, Vincent
Maleux, Geert
Pinna, Antonio D
Bester, Lourens
Morris, David L
Iannitti, David
Chow, Pierce K
Stubbs, Richard
Gow, Paul J
Masi, Gianluca
Fisher, Kevin T
Lau, Wan Y
Kouladouros, Konstantinos
Katsanos, Georgios
Ercolani, Giorgio
Rotellar, Fernando
Bilbao, José I
Schoen, Michael
Date of Publication: 27-Jun-2017
Citation: Annals of Surgical Oncology 2017; online first: 27 June
Abstract: BACKGROUND: Reports show that selective internal radiation therapy (SIRT) may downsize inoperable liver tumors to resection or transplantation, or enable a bridge-to-transplant. A small-cohort study found that long-term survival in patients undergoing resection following SIRT appears possible but no robust studies on postsurgical safety outcomes exist. The Post-SIR-Spheres Surgery Study was an international, multicenter, retrospective study to assess safety outcomes of liver resection or transplantation following SIRT with yttrium-90 (Y-90) resin microspheres (SIR-Spheres®; Sirtex). METHODS: Data were captured retrospectively at participating SIRT centers, with Y-90 resin microspheres, surgery (resection or transplantation), and follow-up for all eligible patients. Primary endpoints were perioperative and 90-day postoperative morbidity and mortality. Standard statistical methods were used. RESULTS: The study included 100 patients [hepatocellular carcinoma: 49; metastatic colorectal cancer (mCRC): 30; cholangiocarcinoma, metastatic neuroendocrine tumor, other: 7 each]; 36% of patients had one or more lines of chemotherapy pre-SIRT. Sixty-three percent of patients had comorbidities, including hypertension (44%), diabetes (26%), and cardiopathy (16%). Post-SIRT, 71 patients were resected and 29 received a liver transplant. Grade 3+ peri/postoperative complications and any grade of liver failure were experienced by 24 and 7% of patients, respectively. Four patients died <90 days postsurgery; all were trisectionectomies (mCRC: 3; cholangiocarcinoma: 1) and typically had one or more previous chemotherapy lines and presurgical comorbidities. CONCLUSIONS: In 100 patients undergoing liver surgery after receiving SIRT, mortality and complication rates appeared acceptable given the risk profile of the recruited patients.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16719
DOI: 10.1245/s10434-017-5950-z
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/28653161
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.